Analysis of the Functional Role of Steroid Receptor Coactivator-1 in Ligand-Induced Transactivation by Thyroid Hormone Receptor
M. Jeyakumar,
Michael R. Tanen and
Milan K. Bagchi
The Population Council and The Rockefeller University, New York,
New York 10021
 |
ABSTRACT
|
---|
The nuclear hormone receptors belonging to the
steroid/thyroid/retinoid receptor superfamily are ligand-inducible
transcription factors. These receptors modulate transcription of
specific cellular genes, either positively or negatively, by
interacting with specific hormone response elements located near the
target promoters. Recent studies indicated that the hormone- occupied,
DNA-bound receptor acts in concert with a cellular coregulatory factor,
termed coactivator, and the basal transcription machinery to mediate
gene activation. Consistent with this scenario, a number of nuclear
proteins with potential coactivator function have been isolated. In the
present study, we demonstrate that steroid receptor coactivator-1
(SRC-1), a recently isolated candidate coactivator, functions as a
positive regulator of the thyroid hormone receptor (TR)-mediated
transactivation pathway. In transient transfection experiments,
coexpression of SRC-1 significantly enhanced ligand-dependent
transactivation of a thyroid hormone response element (TRE)-linked
promoter by human TRß. Our studies revealed that deletion of six
amino acids (451456) in the extreme COOH-terminal region of TRß
resulted in a receptor that retained the ability to bind
T3 but failed to be stimulated by SRC-1. These
six amino acids are part of an amphipathic helix that is highly
conserved among nuclear hormone receptors and contains the core domain
of the ligand-dependent transactivation function, AF-2. In agreement
with this observation, in vitro protein binding studies
showed that SRC-1 interacted with a ligand binding domain peptide
(145456) of TRß in a T3-dependent manner,
whereas it failed to interact with a mutant ligand binding domain
lacking the amino acids (451456). We demonstrated that a synthetic
peptide containing the COOH-terminal amino acids (437456) of TRß
efficiently blocked the ligand-induced binding of SRC-1 to the
receptor. These results suggest that the conserved amphipathic helix
that constitutes the AF-2 core domain of TRß is critical for
interaction with SRC-1 and thereby plays a central role in
coactivator-mediated transactivation. We further observed that a
heterodimer of TRß and retinoid X receptor-
(RXR
), either in
solution or bound to a DR+4 TRE, recruited SRC-1 in a
T3-dependent manner. The AF-2 of TR was clearly
involved in this process because a TR-RXR heterodimer containing a
mutant TRß (1450) with impaired AF-2 failed to bind to SRC-1.
Surprisingly, the RXR-specific ligand 9-cis-retinoic acid
induced binding of SRC-1 to the RXR component of the TRE-bound
heterodimer. This novel finding suggests that RXR, as a heterodimeric
partner of TR, has the potential to play an active role in
transcriptional regulation. Our results raise the interesting
possibility that a RXR-specific ligand may modulate
T3-mediated signaling by inducing additional
interactions between TRE-bound TR-RXR heterodimer and the coactivator.
 |
INTRODUCTION
|
---|
The thyroid hormone receptors (TRs),
and ß, which mediate
the physiological actions of thyroid hormones, belong to the nuclear
hormone receptor superfamily of ligand-inducible transcription factors
that also includes receptors for steroid hormones, retinoids, and
vitamin D3 (1, 2, 3, 4). TR interacts with distinct DNA
sequences, termed thyroid hormone response elements (TREs), in the
target gene promoter and functions either as a transcriptional
activator or a repressor depending on the hormonal status of the
receptor (5). In the absence of hormone, TR functions as a silencer of
basal level transcription from the target promoter (6, 7, 8, 9, 10, 11). Ligand
binding to TR releases transcriptional silencing and leads to the
activation of target gene expression (6, 7, 8, 9). The precise mechanisms by
which TR exerts its transcriptional effects on a TRE-linked promoter
are unclear.
Recent studies in several laboratories indicate that nuclear receptors
repress or enhance transcription by interacting with multiple cellular
coregulatory factors, which function as signaling intermediates between
the receptors and the RNA polymerase II transcription machinery (for a
review see 12 . We and others have demonstrated that unliganded TR
associates with a negative coregulatory factor, termed corepressor
(13, 14, 15, 16, 17). The receptor-corepressor complex binds to the TRE and
actively represses target gene transcription by impairing the activity
of the basal transcription machinery (13, 14, 15, 16, 17). The binding of
T3 to TR results in the dissociation of the corepressor
from the receptor, leading to the reversal of transcriptional
repression (13, 14, 15, 16, 17). The hormone-occupied, DNA-bound receptor is then
believed to act in unison with a positive coregulatory factor, termed
coactivator, to mediate gene activation (9, 14). The coactivators are
envisioned to act as bridging molecules between the activation
domain(s) of the receptor and the basal transcription machinery.
Studies by Chambon and co-workers (18, 19) utilizing transcriptional
interference or squelching between different steroid receptors
first suggested that cofactors in addition to the activated hormone
receptor and the basal transcription apparatus are necessary for gene
activation. We observed recently that ligand-occupied TR, TR
or
TRß, inhibits transactivation of a progesterone-responsive reporter
gene by progesterone receptors in CV1 or human breast carcinoma T47D
cells (20). The transcriptional interference occurred in the absence of
a DNA response element for the interfering receptor (TR) in the
target promoter. It was also totally dependent on the presence of the
hormonal ligand T3. Conceptually, the target protein(s) of
an inhibitory cross-talk between two different nuclear receptors is one
or more basal transcription factors or coactivator(s). We demonstrated
that T3-occupied TR ligand-binding domain (LBD) could bind
to and functionally deplete a soluble cofactor(s) that is critical for
transactivation of a progesterone-responsive gene in T47D nuclear
extracts, while the basal level of trancription from a minimal TATA
promoter or activated transcription from a control adenovirus
major-late promoter remained unaffected (20). These results provided
strong biochemical evidence in favor of the existence of a common,
limiting coactivator molecule that mediates the interaction of
ligand-bound steroid or TR with the RNA polymerase II transcription
machinery to achieve the activated level of the target gene
expression.
Consistent with this scenario, a number of putative mediator proteins
have been isolated during the past 2 yr by a number of laboratories
using yeast two-hybrid assay or far-Western cloning (12, 21, 22, 23, 24, 25, 26, 27, 28, 29).
Screening of cDNA libraries employing baits containing the LBDs of
nuclear receptors led to the isolation of multiple candidate
coactivators such as steroid receptor coactivator-1 (SRC-1) (23), SUG-1
(24), transcriptional intermediary factor-1 (TIF-1) (25),
receptor-interacting protein-140 (RIP-140) (26), TIF-2 (27),
glucocorticoid receptor-interacting protein 1 (GRIP1) (28), p160 (21, 29), and CREB-binding protein (CBP) (29). It is now clear that SRC-1,
p160, TIF-2, and GRIP1 are members of a family of structurally related
coregulatory factors, which significantly enhance transactivation by
several nuclear receptors in the presence of the cognate ligand (23, 27, 28, 29). It has also been reported that each of these proteins
interacts directly with a nuclear receptor in a ligand-dependent manner
(23, 24, 25, 26, 27, 28, 29). However, the molecular interactions between a coactivator
such as SRC-1 and the transactivation domain(s) of a nuclear receptor
have not been explored in detail.
In this study, we analyzed the functional interactions between SRC-1
and a TR-retinoid X receptor (RXR) heterodimer to investigate the
mechanisms of action of the coactivator in TR-mediated transactivation.
Using transient transfection experiments, we demonstrated that SRC-1
functions as a transcriptional coactivator for hormone-occupied TRß.
A conserved COOH-terminal amphipathic
-helix in the LBD of TRß is
essential for ligand-induced interaction with the coactivator. We
provide strong evidence that this conserved
-helix is necessary for
interactions with SRC-1. We also observed that both receptor partners
within a DNA-bound TR-RXR heterodimer display the ability to recruit
SRC-1. Interaction of the coactivator with each partner of the
heterodimer depends on the cognate hormonal ligand. These results
suggest a plausible mechanism by which a combination of TR- and
RXR-specific hormonal signals in a target cell may influence the
transcriptional activity of a TRE-linked promoter by simultaneously
activating both partners within a TR-RXR heterodimer.
 |
RESULTS
|
---|
A Conserved AF-2 Core Domain of TRß Is Essential for Coactivator
Function of SRC-1
Previous studies in our laboratory indicated that a limited pool
of cellular coactivator(s) is critical for efficient TR-mediated
transactivation (20). An array of putative mediator molecules that
interact with nuclear receptors in a ligand-dependent manner have been
isolated recently by different laboratories (21, 22, 23, 24, 25, 26, 27, 28, 29). Onate et
al. (23) reported that SRC-1, a candidate coactivator, enhanced
hormone-induced transactivation by multiple nuclear receptors including
TR. We examined the effects of coexpression of SRC-1 on
ligand-dependent transcriptional activity of human TRß in CV-1 cells.
As shown in Fig. 1
, T3 induced a 4- to
5-fold TRß-mediated transactivation of a thyroid hormone response
element (TRE)-linked reporter gene in the absence of any cotransfected
SRC-1 (compare lanes 1 and 2). Cotransfection of an expression vector
containing SRC-1 did not affect transcriptional activity of unliganded
TR but led to a dramatic enhancement in transactivation by liganded TR
(lane 4). The SRC-1-induced enhancement of transactivation was
typically about 4-fold over that mediated by TR alone effecting a net
20-fold T3-dependent transactivation of the TRE-linked
promoter (compare lanes 1 and 4). Consistent with the earlier report by
Onate et al., SRC-1 therefore functions as a coactivator of
TRß-mediated transactivation of a TRE-linked promoter in the presence
of T3.

View larger version (31K):
[in this window]
[in a new window]
|
Figure 1. The AF-2 Core Domain of TRß Is Critical for
Coactivator Function of SRC-1
CV-1 cells were transiently transfected with pCI-TRß or
pCI-TRß C6 (2 µg) together with TRE tk-CAT (10 µg)
as a T3-responsive reporter plasmid and pSV ß-gal (2
µg) as an internal control. The expression vector pCI-SRC-1 (2.5
µg) was added as indicated. The cells were treated with or without
T3 (10 nM) as shown for 18 h before
harvesting. CAT assays were performed as described in Materials
and Methods. CAT activity was normalized to ß-galactosidase
activity. The activity in the absence of hormone and SRC-1, but in the
presence of pCI-TRß (lane 1), was taken as 1 and the relative values
for test measurements (lanes 28) were obtained. Three independent
sets of the same experiment were performed, and the results are shown
as mean value ± the average deviation from the mean.
|
|
Conceptually, the coactivator molecule provides the functional link
between the transactivation domain(s) of a ligand-bound nuclear
receptor and the basal transcription machinery during gene activation.
Previous studies localized a ligand-dependent transactivation function
in the extreme C-terminal region (440456) of TRß (9, 30, 31). This
region, known as AF-2 core domain, forms an amphipathic
-helix that
contains amino acid residues that are highly conserved among the
nuclear hormone receptors and has been shown to be critical for the
ligand-dependent transactivation by these receptors (9, 30, 31).
Baniahmad et al. (9) previously showed that deletion of the
last six carboxy-terminal amino acids (451456) in TRß resulted in a
mutant receptor, TRß
C6, which retained the ability to
bind thyroid hormone but was impaired in AF-2 function.
To determine whether the AF-2 core domain of TR is involved in
coactivator function, we employed transient transfection to examine the
effects of SRC-1 on transcriptional activity of TRß
C6.
As reported previously, we found that this TR mutant failed to
transactivate a TRE-linked promoter in a T3-dependent
manner (Fig. 1
, lanes 5 and 6). Cotransfection of a vector expressing
SRC-1, which markedly enhanced transactivation by full-length TRß,
did not exhibit any effect on transcriptional activity of the AF-2
mutant either in the presence or in the absence of T3
(lanes 7 and 8). These results clearly implied that conserved amino
acids 451456 within the C-terminal AF-2 core domain of TRß play a
critical role in the coactivator function of SRC-1.
AF-2 Core Domain of TRß Is Essential for Ligand-Dependent
Interaction with SRC-1
Since SRC-1 functions as a transcriptional coactivator for TR, it
is likely to undergo protein-protein interactions with the ligand-bound
receptor. We therefore examined the interaction between SRC-1 and TRß
in vitro. A recombinant TRß fused to
glutathione-S-transferase (GST) was used in this experiment.
As shown in Fig. 2A
, very little binding of
35S-labeled SRC-1 to GST-TRß immobilized on an affinity
matrix was detected in the absence of T3 (lane 2). In the
presence of T3, however, we observed a remarkable
enhancement in the binding of SRC-1 to GST-TRß (lane 3). These
results demonstrated that TRß undergoes direct interaction with SRC-1
in a strictly ligand-dependent manner.

View larger version (12K):
[in this window]
[in a new window]
|
Figure 2. The AF-2 Core Domain of TRß Is Essential for
Ligand-Dependent Interaction with SRC-1
Panel A, 35S-labeled SRC-1 was produced by
in vitro transcription-coupled translation and incubated
with GST (lane 1, 1 µg) or purified GST-TRß (lanes 2 and 3, 1 µg)
immobilized on GSH-resin either in the presence or absence of
T3 (1 µM). After stringent washings, the
resin-bound proteins were eluted with a gel-loading buffer, analyzed by
SDS-PAGE, and visualized by fluorography. A 130-kDa polypeptide
representing full-length SRC-1 is indicated by an arrow.
Smaller 35S-labeled fragments represent truncated forms of
SRC-1 generated during in vitro
transcription-translation. Three independent sets of the same
experiment were performed, and the results of a representative
experiment are shown. Panel B (top), linear structures
of TRß and its deletion mutants. Panel B (middle),
Various deletion mutants of TRß were expressed as GST fusion proteins
in E. coli BL21. The numbers indicate
amino acid end points of the truncated receptor. Each GST-tagged mutant
(1 µg) was immobilized on glutathione-resin and incubated with
35S-labeled SRC-1 produced by in vitro
transcription-coupled translation either in the presence (1
µM) or absence of T3. The resin-bound
proteins were washed extensively, eluted, and analyzed by SDS-PAGE
followed by fluorography. Panel B (bottom), the
absorbance values of the SRC-1 signals (indicated by
arrow) were determined by densitometry. The plotted
values (lanes 49) were adjusted by deducting the background value of
SRC-1 retained nonspecifically on the GST resin alone (lane 2 or 3).
The input lane represents 20% of the total volume of reticulocyte
lysate added to each reaction. Three independent sets of the same
experiment were performed, and the results of a representative
experiment are shown.
|
|
We next investigated the role of the AF-2 core domain of TRß in
ligand-dependent interaction with SRC-1. For this purpose, we analyzed
the interaction of SRC-1 with a panel of TRß deletion mutants (Fig. 2B
, top panel). We observed that the LBD fragment of TRß
containing the amino acids (145456) exhibited remarkable
ligand-dependent binding to SRC-1 (middle and bottom panels,
lanes 4 and 5). By our estimate, about 20-fold enhancement in SRC-1
binding to GST-TR (145456) was observed in the presence of
T3 (bottom panel, compare lane 4 with lane 5).
In contrast, a fragment of TRß containing the N-terminal amino acids
(1260) showed only modest (about 2-fold) ligand-independent binding
to SRC-1 (middle and bottom panels, compare lane 8 or 9 with
lane 4). Interestingly, a receptor mutant GST-TR (82450) that lacked
the N terminus, as well as the last six COOH-terminal amino acids, but
retained hormone binding, failed to exhibit any interaction with SRC-1
either in the presence or in the absence of T3 (lanes 6 and
7). Thus, the deletion of critical amino acids (451456) within the
AF-2 core domain of TRß, which results in the loss of ligand-induced
transcriptional activity of this receptor, also disrupts the
interaction between the receptor and SRC-1. Taken together, these
results prompt us to propose that the conserved AF-2 core domain of TR
critically influences the ligand-dependent interaction between SRC-1
and the receptor.
A 20-Amino Acid Synthetic Peptide Containing the AF-2 Core Domain
of TRß Blocks the Interaction between the Receptor and SRC-1
Danielian et al. (30) and others (9, 31) have
identified a 17-amino acid AF-2 core region containing an amphipathic
-helix whose main features are well conserved between all known
nuclear receptors that transactivate in a hormone-dependent manner.
Point mutations within the AF-2 core domain decrease or abolish
ligand-dependent activation, even though the ligand binding, DNA
binding, and dimerization properties remain unaffected (9, 31).
Furthermore, this domain displays an autonomous activation function
when fused to a heterologous DNA binding domain (9, 31). Recent crystal
structure analyses of the nuclear receptors TR, retinoid acid receptor
(RAR), and RXR suggest that induction of AF-2 activity upon ligand
binding corresponds to a major conformational change involving the
repositioning of the
-helix containing the AF-2 core domain
(32, 33, 34). These observations raised the possibility that this domain is
involved in creating the surface that interacts directly with a
transcriptional coactivator such as SRC-1. We reasoned that if this
postulation is correct, then a peptide containing the AF-2 core domain
might be able to disrupt the binding of the full-length receptor to
SRC-1 by occluding the coactivator-binding site.
To examine this possibility, we synthesized a peptide containing the
last 20 C-terminal amino acids (437456) containing the AF-2 core
domain of TRß. A control peptide containing the same region but
harboring mutations in several key amino acids, which are known to be
critical for AF-2 activity (9, 31), was also generated (Fig. 3
, top panel). We then incubated ligand-bound
TRß with 35S-labeled SRC-1 in the presence or in the
absence of excess AF-2 core or control peptide. As shown in Fig. 3
(middle panel), incubation with an excess of the control
peptide did not significantly affect the ligand-induced binding of
SRC-1 to TRß (compare lane 2 with lane 5 or 6). Incubation with a
similar excess of the AF-2 core peptide, on the other hand, drastically
inhibited the binding of SRC-1 to hormone-occupied TRß (compare lane
2 with lanes 3 or 4). We observed that approximately 50% of
[35S]SRC-1 binding to 2 pmol of TRß was suppressed in
the presence of 10 nmol of AF-2 core peptide (Fig. 3
, bottom
panel). One can consider two different mechanisms by which the
AF-2 core domain may inhibit coactivator binding. It is conceivable
that the AF-2 core helix itself might represent a discrete binding site
for the coactivator. In this scenario, the AF-2 core peptide competes
with the TR LBD for the same binding site on the SRC-1. Alternatively,
the AF-2
-helix may align with another region(s) of the receptor to
generate the proper binding surface for the coactivator. In this latter
scenario, the peptide may inhibit SRC-1 binding by disrupting the
intramolecular interaction that creates the coactivator binding site.
Either way, interference of SRC-1 binding to the full-length receptor
by the AF-2 core peptide strongly suggests that the C-terminal
amphipathic
-helix of TRß is critically involved in creating the
surface in the activated receptor that interacts with the
coactivator.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 3. A Synthetic Peptide Containing the AF-2 Core Domain
Efficiently Blocks SRC-1 Binding by TRß
Top panel, The amino acid sequences of the synthetic
AF-2 core peptide and the control peptide are shown. The positions of
the point mutations in the control peptide that abolish ligand-induced
transactivation by TR are indicated by asterisks.
Middle panel, Purified GST-TRß (2 pmol) was
immobilized on GSH-resin and treated with T3 (1
µM). The immobilized ligand-occupied TRß was then
incubated with 35S-SRC-1 (10 µl) in the absence (lane 2)
or in the presence of increasing amounts of a synthetic AF-2 core
peptide (lane 3, 50 nmol; lane 4, 100 nmol) or the control peptide
(lane 5, 50 nmol; lane 6, 100 nmol). The resin-bound proteins were
processed and analyzed by SDS-PAGE as described in Materials and
Methods. Three independent sets of the same experiment were
performed, and the results of a representative experiment are shown.
Bottom panel, The AF-2 core peptide inhibits
35S-SRC-1 binding to TRß in a dose-dependent manner. The
value for 35S-SRC-1 bound to GST-TRß in the presence of
T3 and in the absence of any added peptide is taken as
100%. Open and closed circles indicate
the amounts of 35S-SRC-1 that remained bound to TRß in
the presence of the indicated amounts of the control and the AF-2 core
peptides, respectively.
|
|
Both Receptor Partners in a TR-RXR Heterodimer Can Interact with
SRC-1 in a Ligand-Dependent Manner
TR forms an obligate heterodimer with RXR, which exists
ubiquitously in all tissues (3, 35). These heterodimers are readily
generated either in solution or on appropriate DNA response elements.
Heterodimerization with RXR markedly enhances binding of TR to its
response element (3, 35). It is thus likely that TR-RXR heterodimers
may represent the functional form of TR in vivo. We
therefore investigated how each receptor partner within a TR-RXR
heterodimer interacts with SRC-1 in response to its cognate hormone. In
this experiment, described in Fig. 4
, we used
bacterially expressed GST-tagged RXR and hexahistidine-tagged TRß.
The GST-RXR fusion protein was first immobilized on glutathione
affinity resin. The TR-RXR heterodimers were generated in the absence
of DNA by incubating the immobilized RXR with excess TRß. The
formation of heterodimers in solution was ascertained by isolating the
immobilized complexes, followed by analysis of the protein components
by SDS-PAGE and by protein staining. Equivalent intensities of TR- and
RXR-specific bands representing equivalent molar amounts of the
receptors were visualized in the isolated complexes confirming
efficient heterodimer formation under these conditions (Fig. 4A
). The
heterodimerization was not significantly affected by the presence of
either a combination of T3 (1 µM) and
9-cis-retinoic acid (RA) (1 µM) (compare lanes
2 and 3 with lanes 6 and 7) or excess direct repeat (DR)+4 TRE (compare
lane 2 with lane 3, lane 6 with lane 7). The resin complexed to TR-RXR
heterodimers was isolated by brief centrifugation and washed
repeatedly. The resin-bound receptors were then treated with either
T3 or 9-cis-RA or solvent follwed by incubation
with 35S-labeled SRC-1.

View larger version (23K):
[in this window]
[in a new window]
|
Figure 4. Both Partners of a TR-RXR Heterodimer Display
Ligand-Dependent Binding to SRC-1
Panel A, Purified GST-RXR (10 pmol) was immobilized on GSH-resin and
incubated with (lanes 2, 3, 6, and 7) or without (lanes 1 and 5) excess
purified His6-TRß (40 pmol). In lanes 4 and 8, GSH-resin
was incubated with His6-TRß (40 pmol) alone. DR+4 TRE (1
µg) and ligands T3 (1 µM) and
9-cis-RA (1 µM) were added during
incubation as indicated. Binding was allowed to proceed for 1 h at
4 C in a buffer containing 20 mM Tris-HCl (pH 7.4), 60
mM NaCl, 1 mM dithiothreitol, and 15%
glycerol. The unbound proteins were removed by washing the resin
repeatedly with the same buffer. The bound proteins retained on the
resin were then eluted by boiling with a gel-loading buffer containing
SDS, analyzed by SDS-PAGE, and visualized by Coomassie blue staining.
Note that the GST portion of GST-RXR contributes to the slightly
better Coomassie blue staining exhibited by this fusion protein
compared with His6-TRß. Panel B (upper),
GST-RXR (10 pmol) was immobilized on GSH-resin and incubated with
excess His6-TRß (lanes 3, 5, and 7, 20 pmol; lanes 4, 6,
8, and 9, 40 pmol) to form heterodimers. The unbound proteins were
washed off the resin. The immobilized heterodimers were then treated
with T3 or 9-cis-RA (1 µM) as
indicated. The resin-bound hormone-receptor complexes were incubated
with 10 µl retic lysate containing 35S-SRC-1. The
resin-bound proteins were finally processed and analyzed by SDS-PAGE as
described in Materials and Methods. Panel B
(lower), the absorbance values of the SRC-1 signals
(indicated by arrow) were determined by densitometry.
The plotted values (lanes 19) were adjusted by deducting the
background value of SRC-1 retained nonspecifically on the GST resin
alone (lane GST). Three independent sets of the same experiment were
performed, and the results of a representative experiment are shown.
|
|
As shown in Fig. 4B
, resin-bound GST-RXR or GST-RXR-TR did not retain
any significant SRC-1 signal in the absence of any hormone (lanes 1, 5,
and 6). Addition of the RXR-specific ligand, 9-cis-RA, led
to a marked enhancement in the binding of SRC-1 to GST-RXR alone
(lower panel, compare lanes 1 and 2). Interestingly,
heterodimerization with TR did not affect 9-cis-RA-dependent
binding of SRC-1 to RXR (compare lane 2 with lanes 3 or 4). Our results
also clearly showed that RXR in a preformed heterodimer could bind to
its ligand and recruit SRC-1 in a ligand-dependent manner (lanes 3 or
4). As expected, addition of T3 to the heterodimer also
markedly induced interaction of SRC-1 with the TR component (lanes 7
and 8). Taken together, these results demonstrated that in a TR-RXR
heterodimer both receptor partners are capable of interacting with a
transcriptional coactivator in a strictly ligand-dependent fashion.
Ligand-Dependent Recruitment of SRC-1 by a DNA-Bound TR-RXR
Heterodimer
It is conceivable that a DNA response element may modulate
interaction of a TR-RXR heterodimer with SRC-1. A recent report
indicated that the polarity or relative configuration of half-sites
within a retinoid response element dictates the interaction of a
RAR-RXR heterodimer with a nuclear receptor corepressor (14). A TR-RXR
heterodimer binds to a DNA response element consisting of two direct
repeat half-sites (DR+4) of consensus sequence AGGTCA in an asymmetric
manner: RXR occupies the upstream half-site and TR occupies the
downstream half-site (36, 37). We therefore examined whether the
binding of a TRß-RXR
heterodimer to the DR+4 TRE influences its
interaction with SRC-1. For this purpose, we first assembled TR-RXR
heterodimers on biotinylated DR+4 TRE oligodeoxynucleotides. The
DNA-bound TR-RXR complexes were then isolated by binding to an
avidin-linked resin, and the resin-bound heterodimers were incubated
with 35S-labeled SRC-1 either in the presence or in the
absence of T3 or 9-cis-RA. After stringent
washings, the resin-bound proteins were analyzed by SDS-PAGE for the
presence of 35S-labeled SRC-1. The results of these
experiments are shown in Fig. 5
, A and B.

View larger version (23K):
[in this window]
[in a new window]
|
Figure 5. Ligand-Dependent Interactions between SRC-1 and a
TR-RXR Heterodimer Bound to a DR+4 Element
Panel A (upper), 1 µg of double-stranded, biotinylated
DR+4 oligonucleotide was immobilized on avidin-linked agarose. The
resin-bound DNA was initially incubated without (lane 3) or with
His6-TRß (lanes 49, 20 pmol) and
His6-RXR (lanes 49, 80 pmol). The resin-DNA-protein
complexes were then treated with T3 or
9-cis-RA (1 µM) as indicated. The
resulting resin-bound complexes were reacted with 10 µl retic lysate
containing 35S-SRC-1. The resin-bound proteins were
processed and analyzed by SDS-PAGE as described in the Materials
and Methods. Panel A (lower), the absorbance
values of the SRC-1 signals (indicated by arrow) were determined by densitometry. The
plotted values (lanes 39) were adjusted by deducting the background
value of SRC-1 retained nonspecifically on the resin alone (lane 2).
The input lane represents 20% of the total volume of reticulocyte
lysate containing labeled SRC-1 that is added to each reaction. Panel B
(upper), 1 µg of double-stranded, biotinylated DR+4
oligonucleotide was immobilized on avidin-linked agarose. The
resin-bound DNA was initially incubated with His6-TRß (20
pmol) alone (lanes 13) or His6-RXR (80 pmol) alone
(lanes 46) or with a combination of both (lanes 711). The
resin-DNA-protein complexes were then treated with T3 or
9-cis-RA (1 µM) as indicated. In certain
control experiments (lanes 1, 2, 4, 5, 7, 8, and 10), the indicated
proteins were incubated with avidin-linked agarose containing no bound
DNA. The resulting resin-bound complexes were reacted with 10 µl of
retic lysate containing 35S-SRC-1. The resin-bound proteins
were processed and analyzed by SDS-PAGE as described in
Materials and Methods. Panel B (lower),
the absorbance values of the SRC-1 signals (indicated by
arrow) were determined by densitometry. Panel C
(upper), immobilized biotinylated DR+4 oligonucleotides
were initially incubated with His6-RXR (lanes 14, 80
pmol) together with either His6-TRß (lanes 1 and 2, 20
pmol) or His6-TRß C6 (lanes 3 and 4, 20
pmol). This was followed by treatment with T3 (1
µM) or 9-cis RA (1 µM) as
indicated. Panel C (lower), the absorbance values of the
SRC-1 signals (indicated by arrow) were determined by
densitometry. The plotted values (lanes 16) were adjusted by
deducting the background value of SRC-1 retained nonspecifically on the
resin alone (data not shown). The input lane represents 20% of the
total volume of reticulocyte lysate containing labeled SRC-1 that is
added to each reaction.
|
|
We noted that low levels of SRC-1 were bound nonspecifically to the
avidin-linked resin in the absence of DNA (Fig. 5A
, lane 2). This
nonspecific retention of SRC-1 was not significantly affected when the
resin was incubated with biotinylated TRE alone (lane 3) or with TR and
RXR in the absence of TRE (lanes 8 and 9). The results in Fig. 4A
suggest that a heterodimer is generated on the DR+4 TRE when one
receptor partner is incubated with DNA in the presence of an excess of
the other partner. The binding of SRC-1 increased only slightly when
resin-bound TRE-TR-RXR complexes were used in the absence of any
hormonal ligand (lane 4). A pronounced enhancement in the binding of
SRC-1 was observed only when resin-bound TRE-TR-RXR complexes were
incubated with the 35S-labeled protein in the presence of
either T3 or 9-cis-RA (upper and
lower panels, compare lane 4 with lane 5 or 6). These
results were in excellent agreement with those described in Fig. 4B
using TR-RXR heterodimers formed in solution. Coaddition of both
ligands did not produce any significant change in SRC-1 binding
compared with each ligand added singly (compare lane 5 or 6 with lane
7). The limiting amount of SRC-1 in the binding reaction did not allow
us to determine whether the two ligand-occupied receptors in a
heterodimer bound to the coactivator in an additive or a synergistic
fashion.
We also examined the binding of 35S-labeled-SRC-1 to the
DR+4-bound resin when TR or RXR was used singly (Fig. 5B
). Previous
reports indicated that TR alone could bind to DR+4 either as a monomer
or homodimer (5, 38, 39). It has been reported that in the presence of
T3, TR homodimers are destabilized whereas the binding of
TR monomers to DR+4 TRE is favored (38, 39). Our results indicated that
TR alone could bind to the TRE under the conditions of our experiment
and recruit SRC-1 in a T3-dependent manner (compare lanes 1
and 2). Upon addition of excess RXR to TR, heterodimers formed on DR+4
TRE, and these complexes also bound to SRC-1 in a
T3-dependent manner (lanes 7 and 8). Although the binding
of TR monomer and homodimer is weaker than the heterodimer, the amount
of SRC-1 recruited by TR-RXR was found to be only slightly greater than
that recruited by TR alone (compare lanes 2 and 8). This observation
was not surprising, however, because the molar concentration of
DNA-bound receptor complexes in the binding reaction far exceeded that
of SRC-1.
We also observed that RXR by itself failed to bind to DR+4 TRE and,
consequently, no significant recruitment of SRC-1 was detected on this
DNA element when RXR alone was used (lanes 4 and 5). Interestingly, a
marked 9-cis-RA-induced SRC-1 binding to the DNA-bound
complex was observed only when a combination of RXR and TR was
incubated with DR+4 (lanes 9 and 10). The simplest explanation for this
observation is that a TR-RXR heterodimer is the predominant complex on
the DR+4 TRE when both receptors are incubated together with this DNA.
It is also evident from these studies that each receptor partner within
the heterodimer positioned at the TRE binds to its cognate ligand and
is able to recruit the coactivator in an entirely ligand-dependent
manner.
We next investigated whether T3-induced recruitment of
SRC-1 by a TR-RXR heterodimer was dependent on an intact AF-2 of TR.
For this purpose, we used the mutant TRß
C6 with impaired AF-2
activity. As shown in Fig. 5B
, whereas a DNA-bound heterodimer
containing a full-length TR displayed strong T3-dependent
binding to SRC-1 (compare lanes 1 and 2), a heterodimer of
TRß
C6 and RXR failed to exhibit any interaction with
the coactivator either in the presence or in the absence of
T3 (lanes 3 and 4). These results are in agreement with our
finding that the ligand-dependent AF-2 of TR plays an essential role in
coactivator function. Interestingly, addition of 9-cis-RA
elicited binding of SRC-1 to the TRß
C6-RXR heterodimer
(lane 5). The 9-cis-RA-induced binding of SRC-1 to RXR is
presumably mediated via the AF-2 of this receptor. Although the
deletion of TRß AF-2 did not appear to significantly influence the
9-cis-RA-induced binding of RXR to the coactivator, we
cannot rule out allosteric control of the activity of one heterodimeric
partner by the other as recently proposed by Schulman et al.
(40), especially because the coactivator is limiting in our assays. We
nonetheless conclude that, in the presence of the cognate ligand, each
receptor component of TR-RXR heterodimer requires the AF-2 core domain
for ligand-dependent interactions with SRC-1. This scenario is entirely
consistent with the proposed role of SRC-1 as a coactivator in nuclear
receptor-mediated transactivation.
 |
DISCUSSION
|
---|
The present study analyzes the molecular interactions underlying
the functional role of a newly identified nuclear receptor coactivator,
SRC-1, in the TR-mediated transactivation pathway. A coactivator is
thought to facilitate hormone-dependent gene activation by serving as a
physical link between the transactivation domain of a ligand-occupied
receptor and the basal transcription machinery. In agreement with this
view, coexpression of SRC-1 in transient transfection experiments
markedly enhanced TR- and T3-mediated transactivation of a
target promoter. We found that the regulatory effect of SRC-1 is
critically dependent on the ligand-induced transactivation function
AF-2 of TR. We also observed that SRC-1 is able to interact with both
TR and its heterodimeric partner, RXR, in a ligand-specific manner.
SRC-1 therefore displays many hallmarks of a genuine coactivator for
TR-mediated transactivation.
Our studies reveal that an AF-2 core domain that is conserved among
nuclear receptors plays a central role in SRC-1-mediated
transactivation. In this study, we demonstrate that a 20-amino acid
peptide containing the AF-2 core domain efficiently inhibits the
binding of TR LBD to SRC-1. More importantly, mutations of key acidic
(Glu 452, Glu 455, Asp 456) and hydrophobic (Phe 454) amino acids,
which impair the ligand-induced transactivation by TR (9, 31), also
abolish the ability of the peptide to interfere with SRC-1 binding to
TR. These results provide compelling evidence that the conserved AF-2
core helix of the receptor is essential for interactions with a nuclear
receptor coactivator. Recent crystal structural analysis of the LBDs of
TR, RXR, and RAR suggests that the AF-2 core domain, which forms an
amphipathic
-helix, also known as helix 12, undergoes a striking
conformational transition upon hormone binding (32, 33, 34). In the
unoccupied receptor, the helix 12 projects into the solvent (32). In
the hormone-occupied receptor, the helix folds back toward the receptor
to form a part of the ligand-binding cavity (33, 34). The helix packs
loosely with the hydrophobic residues facing inward toward the
ligand-binding pocket and the charged residues extending into the
solvent (33, 34). It is conceivable that in the hormone-bound receptor,
the helix presents itself as a binding site for the coactivator. As the
hydrophobic residues interact with the ligand-binding core to stabilize
the domain, certain charged residues might be available for direct
interaction with the coactivator. Alternatively, the ligand-induced
repositioning of helix 12 may trigger a reorganization in other parts
of the receptor, creating an interaction surface for the coactivator.
In this scenario, the AF-2 core domain may play a critical role by
participating in intramolecular interactions with another region(s) of
the LBD to help create the proper coactivator-binding site.
Collingwood et al. (41) have recently reported that a
naturally occurring TRß mutant, in which leucine at position 454 in
the AF-2 core domain is changed to valine, still retains its ability to
respond to SRC-1 in transient transfection experiments. The apparent
discrepancy between our results and those of Collingwood et
al. could arise from the use of different TRß mutants in these
studies. In the case of Collingwood et al. (41), the point
mutant L454V retained moderate interactions with SRC-1. Consequently,
in transient transfection assays, overexpressed SRC-1 could still
potentiate transactivation by this mutant TR, presumably by binding to
the altered AF-2 core domain. In contrast, we employed a truncation
mutant, TRß
C6, which lacked several conserved amino acids within
the AF-2 helix. This deletion rendered TRß
C6 completely
ineffective in SRC-1 binding and as a result, this mutant receptor
failed to respond to the coactivator (Fig. 1
).
Although the failure of the AF-2 mutant, TRß
C6, to
respond to SRC-1-mediated activation in our transfection experiments
may appear to be simply due to a disruption in coactivator binding,
more complex scenarios can be considered. Recent studies suggest that
AF-2 core domain may influence the interaction of the receptor with
corepressor molecules (40). Unliganded TR or RAR associates with a
corepressor, which is released from the receptor upon hormone binding
(13, 15, 16). Interestingly, addition of hormone did not affect the
transcriptional activity of the AF-2 mutant (Fig. 1
, lane 6). This is
presumably due to a failure to release the corepressor. Previous
studies have shown that TRß
C6 binds ligand and
undergoes certain conformational changes in response to ligand binding
(42) but remains a constitutive transcriptional repressor (9).
Therefore, hormone binding is not sufficient to dissociate the
corepressor from the AF-2 mutant. Schulman et al. (40) have
recently proposed that the AF-2 core domain itself participates in the
transition from repressive to active state by an as yet unknown
mechanism. One can speculate that the AF-2 helix helps to maintain a
receptor conformation that allows release of corepressor upon hormone
binding. The loss of this structure in the TRß
C6
mutant prevents corepressor release. Based on the crystal structure of
TR, however, deletion of six amino acids from the AF-2 core helix is
not expected to disrupt the compact bound state of the receptor or its
hormone-binding cavity, although subtle alterations in the receptor
conformation cannot be ruled out (34). Alternatively, one can imagine
that the binding of the coactivator to the AF-2 helix of a ligand-bound
receptor serves as the switch that triggers a conformation change,
which in turn facilitates corepressor release. Recent observations by
Glass and co-workers (14) however, imply that interactions with the
corepressor are dominant over the recruitment of coactivators. These
studies also suggest that the DNA response elements can allosterically
control the receptor-corepressor association. Further analyses of the
complex interplay between the DNA-bound nuclear receptor and the
corepressor or coactivator are therefore needed to understand how these
coregulatory molecules modulate the gene-regulatory activity of the
receptor.
A surprising finding of the present studies is the observation that the
ligand 9-cis-RA induced binding of SRC-1 to RXR in a TR-RXR
heterodimer. Previous studies reported that RXR, once heterodimerized,
is incapable of binding its ligand (43, 44). It was proposed that RXR
in the heterodimer enhances DNA binding by the partner receptor but is
a silent partner in transactivation (3, 43, 44). We, however, observed
that heterodimerization of RXR with TR did not prevent its binding to
9-cis-RA or its ligand-dependent interaction with SRC-1.
RXR, therefore, not only binds to its ligand in the context of the
heterodimer, but also maintains its ability to interact with a
transcriptional coactivator. Our results, therefore, suggest a
potentially active role of RXR in TR-mediated transcription. The reason
for the apparent discrepancy between our results and those published
previously is not clear. Our results are in good agreement, however,
with the work reported previously by Kersten et al. (45) and
more recently by Minucci et al. (46). Whereas Kersten
et al. (45) using a fluorescence-based method demonstrated
that RXR in a RAR-RXR heterodimer can bind to its ligand (45), Minucci
et al. employed a differential proteolytic analysis to
conclude that RXR in such a heterodimer not only binds its ligand but
also functions as a transcriptionally active partner by enhancing
retinoid-dependent gene expression (46). However, the role of RXR in
transactivation by the TR-RXR heterodimer is yet to be settled
unequivocally. In light of the conflicting results from different
laboratories, it appears that RXR within a heterodimer may play either
a silent or an active role depending on cell, promoter, and ligand
contexts.
An interesting issue raised by the present study is the differential
transactivation activities displayed by TR and RXR within the
heterodimer in response to the cognate ligand. Although both partner
receptors can individually bind to the coactivator in a
ligand-dependent manner, T3 but not an RXR-specific ligand,
when added alone, activated transcription from a TRE-linked promoter in
transfection assays (43, 46). Minucci et al. (46) reported
that although a RXR-specific ligand, when added singly, failed to
activate a retinoid-responsive promoter, it synergistically stimulated
transcription when added together with a RAR ligand. Taken together,
these studies indicated that a full display of the transcriptional
activity of RXR in a TR-RXR or RAR-RXR heterodimer depends on the
ligand of its heterodimeric partner. It appears that the
transactivation potential of RXR in the heterodimer is somehow masked
in the absence of either T3 or the RAR ligand. It is
possible that a corepressor, which is complexed with the unliganded TR
or RAR in the heterodimer, blocks access of the coactivator to RXR. In
this scenario, addition of either T3 or the RAR ligand,
which triggers the release of the corepressor from the cognate
heterodimeric partner, is obligatory for RXR-dependent
transactivation.
In summary, the results presented here demonstrate that a conserved
AF-2 core domain of TR plays an essential role in interactions with a
transcriptional coactivator, SRC-1, to regulate the activity of a
TRE-linked promoter. Our studies further reveal that RXR, the
heterodimeric partner of TR, also possesses the potential to modulate
T3-mediated signaling by interacting with the coactivator
in a 9-cis-RA-dependent manner. These results provide
interesting insights into the complex molecular interactions among
multiple nuclear receptors and transcriptional coregulatory factors
that determine the response of hormone-regulated promoters to diverse
ligand signals.
 |
MATERIALS AND METHODS
|
---|
Materials
In vitro transcription and nuclease-treated rabbit
reticulocyte lysate translation kits were purchased from Promega Corp.
(Madison, WI.) L-[35S]methionine (>1000
Ci/mmol) was purchased from Amersham (Arlington Heights, IL).
Plasmid Construction
The SRC-1 cDNA used in this study was originally isolated by
Onate et al. (23). The 3432-nucleotide cDNA extends from
positions -62 to + 3361 and contains an open reading frame of 1061
amino acids. The plasmids pCI-TRß and pCI-SRC-1 expressing human
TRß and human SRC-1, respectively, were constructed by inserting
cDNAs encoding these proteins into vector pCI under the control of
human cytomegalovirus immediate-early promoter (Promega).
pCI-TRß
C6 was constructed by incorporating the
previously described mutant TRß
C6 (9) in the pCI
vector. The construction of the reporter plasmid TRE-tkCAT has been
described previously (20).
Recombinant Nuclear Receptors and Their Mutants
Recombinant nuclear receptors GST-TRß and GST-RXR
containing GST fused to the amino-terminal sequences of TRß and
RXR
, respectively, were expressed in Escherichia coli
BL21. Various deletion mutants of TRß were expressed as GST fusion
proteins: GST-TR (145456), GST-TR (80450), and GST-TR (1260). The
receptor fragments were generated by PCR and engineered into the
bacterial expression vector pGX-2T (Pharmacia, Piscataway, NJ). The
construction, expression, and purification of His6-TRß
and His6-RXR
were described previously (11). The protein
concentrations of mutant receptors were determined by comparing the
intensity of Coomassie-stained band of each receptor fusion protein
with that of a known BSA standard in SDS-PAGE.
Transient Transfection Experiments
CV-1 cells were maintained in DMEM (GIBCO BRL, Grand Island, NY)
supplemented with 5% FBS (Hyclone Laboratories, Logan, UT).
Semiconfluent cells were transiently transfected using the calcium
phosphate coprecipitation procedure as described previously (20).
Briefly, 5 x 105 cells were plated on 10-cm tissue
culture dishes in phenol red-free DMEM medium containing 5%
charcoal-stripped serum and after 2448 h were transfected with
plasmid DNAs. Typically, cells received 10 µg chloramphenicol
acetyltransferase (CAT) reporter plasmid, 2 µg pCI-TRß or
pCI-TRß
C6, 2.5 µg pCI-SRC-1 or empty pCI vector, and
2 µg of an internal control plasmid pSV-ßgal (Promega), which
contains the gene for ß-galactosidase enzyme. After 1214 h of
exposure to the calcium phosphate precipitate, the cells were washed
with PBS and incubated in fresh phenol red-free, serum-free medium with
10-8 M T3 or solvent. Cells were
harvested after 18 h for determination of ß-galactosidase and
CAT activities as described previously (20). The amount of cell extract
used per CAT assay was determined after normalization with respect to
the ß-galactosidase activity. Quantification of the CAT activities
was performed by liquid scintillation analysis of the acetylated
[14C]-chloramphenicol product and the remaining
unacetylated substrate. Each transient transfection experiment was
repeated at least three times.
GST Pull-Down Assay
Each GST fusion protein (0.11.0 µg) was immobilized on a
glutathione (GSH)-resin (15 µl), and the immobilized protein was
treated with or without T3 (1 µM) or
9-cis-RA (1 µM) at room temperature for 15
min. 35S-labeled SRC-1 was generated from an expression
vector pBK-CMV-SRC-1 by in vitro transcription-coupled
translation in reticulocyte lysates following manufacturers
instructions. An aliquot (10 µl) of the translation mix containing
labeled SRC-1 was then incubated with immobilized GST fusion protein in
a binding buffer containing 20 mM Tris-HCl (pH 7.4), 60
mM NaCl, 1 mM dithiothreitol, 15% glycerol,
and 0.1% NP-40. Binding was allowed to proceed for 1 h at 4 C.
The resin was then washed repeatedly with the binding buffer. The
35S-labeled SRC-1 that was retained on the resin was eluted
by boiling with a gel-loading buffer containing SDS, analyzed by
SDS-PAGE, and visualized by fluorography.
In peptide competition experiments, GST-TRß (0.1 µg) was first
immobilized on a GSH-resin followed by treatment with T3 (1
µM). The resin-bound hormone-receptor complex was then
incubated with 35S-labeled SRC-1 (10 µl translation mix)
in the presence of increasing molar excess of either AF-2 core or
control peptide. The 35S-labeled SRC-1 that was retained on
the resin after stringent washings was then eluted by boiling with a
gel-loading buffer containing SDS and analyzed by SDS-PAGE. The AF-2
core and control peptides were synthesized by the Rockefeller
University Biopolymer Facility (New York, NY).
Biotinylated DNA Pull-Down Assay
For this assay, the protocol of Kurokawa et al. (14)
was used with certain modifications. The sequence of the sense strand
of the DR+4 TRE was:
5'-GAAGGGGATCCGGGTAAGGTCACAGGAGGTCACGAA-3'. The
sense oligodeoxynucleotide was biotinylated at the 5'-end by using a
biotin-phosphoramidite during synthesis. Equal amounts of sense and
antisense oligonucleotides were annealed to form the double-stranded
DR+4 element. One microgram (
35 pmol) of the double-stranded
oligonucleotide was coupled to 12 µl avidin-linked agarose for 1
h at room temperature. The immobilized biotinylated TRE was then
incubated with purified His6-TRß (20 pmol) or
His6-RXR
(80 pmol) or a combination of both for 30 min
at room temperature. The incubation was performed in a binding buffer
containing 20 mM Tris-HCl (pH 7.4), 60 mM NaCl,
1 mM dithiothreitol, 15% glycerol, and 0.1% NP-40. The
resin was collected by brief centrifugation and washed extensively with
the binding buffer. The resin-bound DNA-receptor complexes were then
treated with either T3 (1 µM) or
9-cis-RA (1 µM) or solvent for 20 min at room
temperature. Ten microliters of translation mix containing
35S-labeled SRC-1 were then added to the receptor-DNA
complexes, and incubation was carried out for 30 min at room
temperature. The resin was again collected and washed repeatedly with
the binding buffer. The bound proteins were eluted with a gel-loading
buffer containing SDS and analyzed by SDS-PAGE. 35S-labeled
SRC-1 was visualized by fluorography. The intensity of the full-length
SRC-1 polypeptide was quantitated by densitometry. The optical
densities were corrected by subtracting from the test values the
nonspecific binding of SRC-1 to the resin in the absence of DNA and the
receptors.
 |
ACKNOWLEDGMENTS
|
---|
We are grateful to Bert W. OMalley and Ming-Jer Tsai for the
generous gift of human SRC-1 cDNA.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Milan K. Bagchi, The Population Council and The Rockefeller University, 1230 York Avenue, New York, New York, 10021.
This work was supported by NIH Grant R01DK-5025702 (to M.K.B).
Received for publication January 31, 1997.
Accepted for publication February 28, 1997.
 |
REFERENCES
|
---|
-
Tsai M-J, OMalley BW 1994 Molecular mechanisms of
action of steroid/thyroid receptor superfamily members. Annu Rev
Biochem 63:451486[CrossRef][Medline]
-
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,
Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The
nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
-
Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers, orphan
receptors. Cell 83:841850[Medline]
-
Beato M, Herrlich P, Schutz G 1995 Steroid hormone receptors:
many actors in search of a plot. Cell 83:851857[Medline]
-
Lazar MA 1993 Thyroid hormone receptors: multiple forms,
multiple possibilities. Endocr Rev 14:184193[Medline]
-
Damm K, Thompson CC, Evans RM 1989 Protein encoded by v-erbA
functions as a thyroid hormone receptor antagonist. Nature 339:593597[CrossRef][Medline]
-
Baniahmad A, Kohne AC, Renkawitz R 1992 A transferable
silencing domain is present in the thyroid hormone receptor, in the
v-erbA oncogene product and in the retinoic acid receptor. EMBO J 11:10151023[Abstract]
-
Casanova J, Helmer E, Selmi-Ruby S, Qi J-S, Au-Fliegner M,
Desai-Yajnik V, Koudinova N, Yarm F, Raaka BM, Samuels HH 1994 Functional evidence for ligand-dependent dissociation of thyroid
hormone, retinoic acid receptors from an inhibitory cellular factor.
Mol Cell Biol 14:57565765[Abstract]
-
Baniahmad A, Leng X, Burris TP, Tsai SY, Tsai M-J, OMalley
BW 1995 The t4 activation domain of the thyroid hormone receptor is
required for release of a putative corepressor(s) necessary for
transcriptional silencing. Mol Cell Biol 15:7686[Abstract]
-
Fondell JD, Roy AL, Roeder RG 1993 Unliganded thyroid hormone
receptor inhibits formation of a functional initiation complex:
implications for active repression. Genes Dev 7:14001410[Abstract]
-
Tong G-X, Tanen MR, Bagchi MK 1995 Ligand modulates the
interaction of thyroid hormone receptor b with the basal transcription
machinery. J Biol Chem 270:1060110611[Abstract/Free Full Text]
-
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung
L 1996 Nuclear receptor coactivators, corepressors. Mol Endocrinol 10:11671177[Abstract]
-
Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa
R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated
by a nuclear receptor co-repressor. Nature 377:397403[CrossRef][Medline]
-
Kurokawa R, Soderstrom M, Horlein AJ, Halachmi S, Brown M,
Rosenfeld MG, Glass CK 1995 Polarity-specific activities of retinoic
acid receptors determined by a co-repressor. Nature 377:451454[CrossRef][Medline]
-
Chen JD, Evans RM 1995 A transcriptional co-repressor that
interacts with nuclear hormone receptors. Nature 377:454457[CrossRef][Medline]
-
Tong G-X, Jeyakumar M, Tanen MR, Bagchi MK 1996 Transcriptional silencing by unliganded thyroid hormone receptor b
requires a soluble corepressor that interacts with the ligand-binding
domain of the receptor. Mol Cell Biol 16:19091920[Abstract]
-
Sande S, Privalsky ML 1996 Identification of TRACs
(T3 receptor-associating cofactors), a family of cofactors
that associate with, modulate the activity of, nuclear hormone
receptors. Mol Endocrinol 10:813825[Abstract]
-
Meyer ME, Gronemeyer H, Turcotte B, Bocquel MT, Tasset D,
Chambon P 1989 Steroid hormone receptors compete for factors that
mediate their enhancer function. Cell 57:433442[Medline]
-
Meyer ME, Qurin-Stricker C, Chambon P, Gronemeyer H 1992 A
limiting factor mediates the differential activation of promoters by
the human progesterone receptor isoforms. J Biol Chem 267:1088210887[Abstract/Free Full Text]
-
Zhang X, Jeyakumar M, Bagchi MK 1996 Ligand-dependent
cross-talk between steroid, thyroid hormone receptors. J Biol Chem 271:1482514833[Abstract/Free Full Text]
-
Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C,
Brown M 1994 Estrogen receptor-associated proteins possible
mediators of hormone-induced transcription. Science 264:14551458[Medline]
-
Lee JW, Choi H-S, Gyuris J, Brent R, Moore DD 1995 Two classes
of proteins dependent on either the presence or absence of thyroid
hormone for interaction with the thyroid hormone receptor. Mol
Endocrinol 9:243254[Abstract]
-
Onate SA, Tsai SY, Tsai M-J, OMalley BW 1995 Sequence
and characterization of a coactivator for the steroid hormone receptor
superfamily. Science 270:13541357[Abstract]
-
Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD 1995 Interaction of thyroid hormone receptor with a conserved
transcriptional mediator. Nature 374:9194[CrossRef][Medline]
-
Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat B,
Heery D, Gronemeyer H, Chambon P, Losson R 1995 The N-terminal part of
TIF1, a putative mediator of the ligand-dependent activation function
(AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein
T 18. EMBO J 14:20202033[Abstract]
-
Cavailles V, Dauvois S, Horset FL, Lopez G, Hoare S, Kushner
PJ, Parker MG 1995 Nuclear factor RIP 140 modulates transcriptional
activation by the estrogen receptor. EMBO J 14:37413751[Abstract]
-
Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent
activation function AF-2 of nuclear receptors. EMBO J 15:36673675[Abstract]
-
Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MRG 1996 RIP1, A novel mouse protein that serves as a transcriptional
coactivator in yeast for the hormone binding domains of steroid
receptors. Proc Natl Acad Sci USA 93:49484952[Abstract/Free Full Text]
-
Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin
S-C, Heyman RA, Rose DW, Glass CK, Rosenfeld MGA 1996 CBP integrator
complex mediates transcriptional activation, AP-1 inhibition by nuclear
receptors. Cell 85:403414[Medline]
-
Danielian PS, White R, Lees JA, Parker MG 1992 Identification
of a conserved region required for hormone-dependent transcriptional
activation by steroid hormone receptors. EMBO J 11:10251033[Abstract]
-
Barettino D, Vivanco Ruiz MM, Stunnenberg HG 1994 Characterization of the ligand-dependent transactivation domain of
thyroid hormone receptor. EMBO J 13:30393049[Abstract]
-
Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear
receptor RXR-
Nature 375:377382[CrossRef][Medline]
-
Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer
H, Moras D 1995 Crystal structure of the RAR-
ligand-binding domain
bound to all-trans retinoic acid. Nature 378:681689[CrossRef][Medline]
-
Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD,
Fletterick RJ 1995 A structural role for hormone in the thyroid hormone
receptor. Nature 378:690697[CrossRef][Medline]
-
Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM 1992 Retinoid x receptor interacts with nuclear receptors in retinoic
acid, thyroid hormone and vitamin D3 signalling. Nature 355:446449[CrossRef][Medline]
-
Kurokawa R, Yu VC, Naar A, Kyakumoto S, Han Z, Silverman
S, Rosenfeld MG, Glass CK 1993 Differential orientations of the
DNA-binding domain, carboxy-terminal dimerization interface
regulate binding site selection by nuclear receptor heterodimers. Genes
Dev 7:14231435[Abstract]
-
Perlmann T, Rangarajan PN, Umesono K, Evans RM 1993 Determinants for selective RAR, TR recognition of direct repeat HR Es.
Genes Dev 7:14111422[Abstract]
-
Yen PM, Darling DS, Carter RL, Forgione M, Umeda PK, Chin WW 1992 Triiodothyronine (T3) decreases binding to DNA by T3-receptor
homodimers but not receptor-auxiliary protein heterodimers. J Biol
Chem 267:35653568[Abstract/Free Full Text]
-
Ribeiro RCJ, Kushner PJ, Apriletti JW, West BL, Baxter JD 1992 Thyroid hormone alters in vitro DNA binding of monomers,
dimers of thyroid hormone receptors. Mol Endocrinol 6:11421152[Abstract]
-
Schulman IG, Juguilon H, Evans RM 1996 Activation, repression
by nuclear hormone receptors: hormone modulates an equilibrium between
active, repressive states. Mol Cell Biol 16:38073813[Abstract]
-
Collingwood TN, Rajanayagam O, Adams M, Wagner R, Cavailles V,
Kalkhoven E, Matthews C, Nystrom E, Stenlof K, Lindstedt G, Tisell
L, Fletterick RJ, Parker MG, Chatterjee VKK 1997 A natural
transactivation mutation in the thyroid hormone b receptor: impaired
interaction with putative transcriptional mediators. Proc Natl Acad Sci
USA 94:248253[Abstract/Free Full Text]
-
Leng X, Tsai SY, OMalley BW, Tsai M-J 1993 Ligand-dependent
conformational changes in thyroid hormone, retinoic acid receptors are
potentially enhanced by heterodimerization with retinoic x
receptor. J Steroid Biochem Mol Biol 46:643661[CrossRef][Medline]
-
Forman BM, Umesono K, Chen J, Evans RM 1995 Unique response
pathways are established by allosteric interactions among nuclear
hormone receptors. Cell 81:541550[Medline]
-
Kurokawa R, Direnzo J, Boehm M, Sugarman J, Gloss B, Rosenfeld
MG, Heyman RA, Glass CK 1994 Regulation of retinoid signaling by
receptor polarity, allosteric control of ligand binding. Nature 371:528531[CrossRef][Medline]
-
Kersten S, Dawson MI, Lewis BA, Noy N 1996 Individual subunits
of heterodimers comprised of retinoic acid, retinoid x receptors
interact with their ligands independently. Biochemistry 35:38163824[CrossRef][Medline]
-
Minucci S, Leid M, Toyama R, Saint-Jeannet J-P, Peterson
V, Horn V, Ishmael JE, Bhattacharyya N, Dey A, Dawid IG, Ozato K 1997 Retinoid x receptor (RXR) within the RXR-retinoic acid receptor
heterodimer binds its ligand, enhances retinoid-dependent gene
expression. Mol Cell Biol 17:644655,[Abstract]